Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. RoC also works to increase patients’ access to medical cannabis by helping U.S.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Veriheal

OCTOBER 20, 2021

Veriheal does not support illegally consuming alternative therapeutic substances but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting psychedelic therapy. A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Cannabis Law Report

AUGUST 2, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.

Research and Development 98

Research and Development Therapy Collective Treatment 98

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

NOVEMBER 3, 2021

This collectively brings the Company’s total clinic count to 15 globally. Khiron in the United Kingdom The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK.

Therapy 52

Therapy Access Patients Treatment 52

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. These doses are produced under Good Agricultural and Collection Practices and tested for potency and impurities to support patient safety and practitioner confidence. investment community.”

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

SEPTEMBER 2, 2021

The Contract contains no minimum testing requirement; it stipulates a fixed monthly fee for sample collection site services and a separate fixed fee per individual COVID-19 test. The initial Contract term is one year and includes two one-year options for renewal exercisable at the College’s discretion.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 3, 2021

ADCL’s solution includes the use of subcontractor CLEARED4’s health verification platform for appointments, sample tracking, and value-add services of campus access management. As prime contractor, ADCL will also provide on-site staffing and sample transport and logistics.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

JANUARY 4, 2022

Assay and Recently Developed, Unsupervised, At-Home Sample Collection Kit to Expand Addressable Market and Scope of COVID-19 Testing Services – STONY BROOK, N.Y.–(BUSINESS Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH. Assay (the “Linea 2.0 Assay (the “Linea 2.0

Conditions 52

Conditions Research and Development Therapy Supply Chain 52

Cannabis Law Report

NOVEMBER 5, 2021

Sample collection for weekly COVID-19 pooled testing can be performed in-person (supervised) or via self-collection kits 1. Negative testing results yield a ‘green pass’ via CLEARED4 that is texted to the employee’s smartphone that authorizes access to corporate facilities. Dr. James A. About Applied DNA Sciences.

Compliance 52

Compliance Compliance Research and Development Therapy 52

Cannabis Law Report

JUNE 17, 2021

Silo Wellness is a publicly traded company on the CSE with a consumer-facing platform for the sale of functional mushroom products, psilocybin mushroom production in Jamaica, and the facilitation of psychedelic wellness retreats in both Jamaica and Oregon that incorporate a variety of psychedelic-augmented therapies. ir@silowellness.com.

Research and Development 75

Research and Development Access Therapy Media 75

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Specifically, the agency fears that.

CBD 90

CBD Safety Topical Food 90

Cannabis Law Report

DECEMBER 7, 2021

Our audacious mission is to create the new standard of trust and transparency consumers deserve and healthcare providers demand on these widely accessible potential therapies. The large scale and intentional heterogeneity of our studies can transform these consumer health products into democratized precision solutions.”.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

OCTOBER 12, 2021

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MARCH 31, 2022

While much of the marketing behind Measure 109 focused on “psilocybin therapy,” there is no requirement for clients to receive a medical diagnosis before accessing services. Currently available data is not fully reliable as there are shortfalls in research methodology and data collection.

Microdosing 52

Microdosing Legalization Dispensary Data 52

Cannabis Law Report

AUGUST 10, 2021

The deal also provides the group with the ability to build upon MTL’s current brand portfolio, and develop a diverse flower menu bringing premium, accessible products to cannabis consumers while maintaining existing supply agreements. Enhanced retail sales portfolio through immediate access to brands distributed in Québec; and.

Seed-To-Sale 105

Seed-To-Sale Cultivation Patients Cannabis 105

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MARCH 19, 2020

They expressed this concern at a public meeting held by FDA in May 2019, explaining that conflicting regulatory requirements create uncertainty that is stifling medical research and hindering consumer access to CBD products. The docket will be open indefinitely, allowing stakeholders to comment and share data with FDA on an ongoing basis.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

NOVEMBER 7, 2019

As of August 2019, authorities in Australia have granted approximately 14,500 approvals, under the Special Access Scheme, for the legal use of medicinal cannabis. Doctor advisory and patient access. The growth potential of the legal medicinal market is tremendous.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Patient and physician are on this rocky journey together, for better or worse. . through international sources, namely Israel. .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

JULY 24, 2022

The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 The collective term psychedelics or hallucinogens respectively (from Latin [h]al[l]ucinatio – thoughtless speech ) covers various substances that cause a perceptual and sensory disorder [2].

Research and Development 52

Research and Development Legalization Treatment Patients 52

Cannabis Law Report

OCTOBER 29, 2019

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. iv Named-patient and compassionate use proceduresThe TG Act provides mechanisms that allow individuals to gain limited access to UTGs (defined in Section II.iii). The institution at which the trial will be conducted gives the final approval.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JUNE 4, 2021

Graham contributes to Psilocybin Alpha as editor-at-large, providing data for patent trackers and writing about IP in the psychedelics space. In 2018, it led to ketamine therapy, and it’s still changing his life. Truffles Therapy. in/gpechenik/ [link]. James Keim. Mimosa Therapeutics. James Keim is a psychotherapist.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51